NTLA vs EDIT
NTLA and EDIT side by side — valuation & fundamentals (public data).
Key statistics
| Metric | NTLAINTELLIA THERAPEUTICS, INC. | EDITEditas Medicine, Inc. |
|---|---|---|
| Market cap | $1.49B | $251.62M |
| P/S | 22.1x | 6.2x |
| Revenue growth (YoY) | 16.9% | 25.4% |
| Earnings growth (YoY) | 20.5% | 32.5% |
| EBIT margin | -651.7% | -394.9% |
| ROE | -66.5% | -3631.1% |
| 1y total return | -8.2% | +2.4% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: NTLA vs EDIT
| Metric | NTLA | EDIT |
|---|---|---|
| End value | $4.8K | $856 |
| Total return | -51.7% | -91.4% |
| CAGR | -6.9% | -21.4% |
| Volatility | 78.4% | 83.5% |
| Sharpe | 0.25 | 0.07 |
| Sortino | 0.37 | 0.10 |
| Max drawdown | -96.5% | -98.9% |
Based on 2573 common trading days, 2016-05-06 → 2026-07-31 · risk-free 3.83% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)